All In Biotech

Drug Trial Radar · NCT03274492

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

Last checked: Nov 20, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,000

Actual

Start

Nov 16, 2017

Primary completion

Apr 30, 2026

Study completion Apr 30, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

  • Polatuzumab VedotinDrug

    Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.

  • RituximabDrug

    Rituximab IV infusion will be administered as per the schedule specified in the respective arm.

  • CyclophosphamideDrug

    Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.

  • DoxorubicinDrug

    Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.

  • VincristineDrug

    Vincristine IV infusion will be administered as per the schedule specified in the respective arm.

  • Vincristine PlaceboDrug

    Placebo matching to vincristine will be administered as per the schedule specified in the respective arm.

  • PrednisoneDrug

    Prednisone PO will be administered as per the schedule specified in the respective arm.

  • Polatuzumab vedotin PlaceboDrug

    Placebo matching to polatuzumab vedotin will be administered as per the schedule specified in the respective arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant LymphomaTime frame: From randomization to the first occurrence of disease progression or relapse, or death from any cause, whichever occurs earlier (up to 38 months)

Locations

209 sites in 22 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Southern Cancer Center

    Daphne, Alabama

  • City of Hope

    Duarte, California

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • Rocky Mountain Cancer Centers, LLP

    Aurora, Colorado

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Florida Cancer Specialists - Fort Myers (New Hampshire Ct)

    Fort Myers, Florida

  • Florida Cancer Specialists & Research Institute

    St. Petersburg, Florida

  • Florida Cancer Specialists & Research Institute

    St. Petersburg, Florida

  • Emory University

    Atlanta, Georgia

  • Illinois Cancer Specialists

    Arlington Heights, Illinois

  • James Graham Brown Cancer Center

    Louisville, Kentucky

  • Ochsner Medical Center

    New Orleans, Louisiana

  • University of Maryland

    Baltimore, Maryland

  • The Johns Hopkins Hospital

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Karmanos Cancer Center

    Detroit, Michigan

  • Washington University

    St Louis, Missouri

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Memorial Sloan Kettering Cancer Center at Westchester

    Harrison, New York

  • New York University Cancer Cen

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center - Commack

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • University of North Carolina School of Medicine

    Chapel Hill, North Carolina

  • Levine Cancer Institute - Clincal Trials Administration

    Charlotte, North Carolina

  • Oncology Hematology Care

    Cincinnati, Ohio

  • The Ohio State University Comprehensive Cancer Center

    Cleveland, Ohio

  • University Hospitals Case Medical Center

    Cleveland, Ohio

  • Oncology Associates of Oregon, P.C

    Eugene, Oregon

  • Northwest Cancer Specialists - Portland (SW Barnes Rd)

    Portland, Oregon

  • Oregon Health & Science University

    Portland, Oregon

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • University of Pittsburgh Cancer Institute

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina (MUSC)

    Charleston, South Carolina

  • Prisma Health ? Upstate

    Greenville, South Carolina

  • Greco-Hainesworth Centers for Research

    Chattanooga, Tennessee

Showing 40 of 209 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.